EU/3/16/1752

Table of contents

About

On 14 October 2016, orphan designation (EU/3/16/1752) was granted by the European Commission to Pfizer Limited, United Kingdom, for human monoclonal IgG1 antibody against tissue factor pathway (also known as PF-06741086) for the treatment of haemophilia A.

The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in November 2018.

Key facts

Active substance
Human monoclonal IgG1 antibody against tissue factor pathway inhibitor
Disease / condition
Treatment of haemophilia A
Date of decision
14/10/2016
Outcome
Positive
Orphan decision number
EU/3/16/1752

Sponsor's contact details

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Tel. +32 2554 6586
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating